A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

June 30, 2016

Conditions
Cancer
Interventions
DRUG

Sativex

Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).

Trial Locations (5)

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

LS9 7TF

St James's Institute of Oncology, St James's University Hospital, Leeds

BS2 8ED

Bristol Haematology & Oncology Centre, Bristol

SE1 7EH

Guy's and St Thomas NHS Foundation Trust, of St Thomas' Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY